Orchid Pharma gets EIR report from USFDA on inspection closure
New Delhi: Drug firm Orchid Pharma has received Establishment Inspection Report (EIR) from the US health regulator on the successful inspection closure for its Irungattukottai formulations plant in Tamil Nadu.
Reacting to the news, shares of the company jumped by 9.91 per cent to settle the day at Rs 64.90.
"Orchid received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) based on the successful inspection closure for the formulation manufacturing facility," at Irungattukottai, the company said in a BSE filing.
The facility was inspected by the USFDA in the month of May 2015, it added.
Establishment Inspection Report (EIR) is given to a establishment after the completion of the inspection by FDA.
Orchid is present in segments such as anti-infectives, anti-inflammatory, central nervous system, cardio vascular, nutraceuticals and oral as well as sterile products.
Reacting to the news, shares of the company jumped by 9.91 per cent to settle the day at Rs 64.90.
"Orchid received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) based on the successful inspection closure for the formulation manufacturing facility," at Irungattukottai, the company said in a BSE filing.
The facility was inspected by the USFDA in the month of May 2015, it added.
Establishment Inspection Report (EIR) is given to a establishment after the completion of the inspection by FDA.
Orchid is present in segments such as anti-infectives, anti-inflammatory, central nervous system, cardio vascular, nutraceuticals and oral as well as sterile products.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.